These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1141 related articles for article (PubMed ID: 19643484)

  • 1. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab.
    Sayanagi K; Sharma S; Yamamoto T; Kaiser PK
    Ophthalmology; 2009 May; 116(5):947-55. PubMed ID: 19232732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
    Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
    Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
    Lai TY; Chan WM; Liu DT; Lam DS
    Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting.
    Querques G; Azrya S; Martinelli D; Berboucha E; Feldman A; Pece A; Coscas G; Soubrane G; Souied EH
    Br J Ophthalmol; 2010 Mar; 94(3):292-6. PubMed ID: 19951942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.
    Vadalà M; Pece A; Cipolla S; Monteleone C; Ricci F; Boscia F; Cillino S
    Retina; 2010 Jun; 30(6):903-7. PubMed ID: 20531143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration].
    Kloos P; Bernasconi P; Estermann S; Bachmann B; Rutishauser Y; Thölen A
    Klin Monbl Augenheilkd; 2008 May; 225(5):385-91. PubMed ID: 18454378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
    Jonas JB; Spandau UH; Harder B; Vossmerbaeumer U; Kamppeter BA
    Am J Ophthalmol; 2005 Jun; 139(6):1073-9. PubMed ID: 15953439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.